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with cirrhosis and hepatocellular carcinoma. She denied
recent usage of alcohol, drugs, or herbs. There was no
recent incident of trauma, exertion, fever, or sepsis. She
developed decompensated cirrhosis, ascites, and esopha-
geal varices with albumin 3 g/dL, aspartate aminotrans-
ferase 250 IU/L, alanine aminotransferase 222 IU/L, total
bilirubin 2.2 mg/dL, direct bilirubin 0.7 mg/dL, interna-
tional normalized ratio for prothrombin time 1.71, creati-
nine 0.74 mg/dL, sodium 138 mmol/L, potassium
3.6 mmol/L, hepatitis B virus deoxyribonucleic acid
5.4  106 IU/mL, and alpha-fetoprotein 656 ng/mL. Both
hepatitis B surface antigen (HBsAg) and hepatitis B e
antigen (HBeAg) were detected to be positive. Telbivudine
was prescribed on admission. Abdominal sonography,
computed tomography, and magnetic resonance imaging
confirmed the presence of two ill-defined tumors (5.8  5.2
and 3.3  2.8 cm2 in size) at the right liver and several
retroperitoneal lymphadenopathies; the inferior vena cava
was invaded by tumorous tissue with complete thrombosis.Conflicts of interest: The authors have no conflicts of interest
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ascites and coagulopathy.
On the 11th day, the patient developed weakness and
myalgia on her lower limbs. Acute idiopathic rhabdomyol-
ysis was confirmed by the laboratory data of creatine
phosphokinase (CPK) 3554 IU/L, CPK-MB 137.5 ng/mL,
Troponin-I 0.04 ng/mL, myoglobin 2415 ng/mL, and lactate
dehydrogenase 1326 IU/L. Acute renal failure was pre-
vented by intensive hydration, urine alkalization and
diuresis. On the 17th day, CPK was at 1831 IU/L and creati-
nine at 0.77 mg/dL despite continuous telbivudine use.
Telbivudine has been reported to cause rhabdomyolysis at
11e21months of treatment1 and was thus unlikely to be the
cause of rhabdomyolysis in this patient.
The patient developed chylous ascites with ascitic
triglyceride level of 335 mg/dL on the 22nd day. The cultures
of ascitic fluids, blood, and urine showed no bacterial
growth. The ascitic fluid showed no atypical cell, and the
adenosine deaminase was 2 U/L. The chylous ascites, which
might have been caused by hepatocellular carcinoma with
retroperitoneal lymphadenopathies, responded poorly to
the low-fat diet with medium-chain triglyceride and
diuretics. Because of deteriorating hepatic failure, the
patient expired on the 30th day.
To our knowledge, this is the first reported case of
combined rhabdomyolysis and chylous ascites in a patient& Formosan Medical Association. All rights reserved.
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patients, the incidence of idiopathic rhabdomyolysis was
1.8%, and the mortality rate ranged from 32.2% to 42.1%,
depending on the patients’ underlying liver function.2
Rhabdomyolysis should be suspected in patients of decom-
pensated cirrhosis with muscular symptoms such as weak-
ness and myalgia.3 Early recognition and treatment may
prevent acute renal failure. Chylous ascites occurs
in 0.5e1.3% of cirrhotic patients.4 Portal hypertension with
excessive lymph flow of up to 20 L/d would cause dilatation
and rupture of lymphatic channels. Chylous ascites
can be used to predict unfavorable outcome in patients with
decompensated liver cirrhosis and hepatic malignancy.
Methods of management of chylous ascites includes
portosystemic shunt, transjugular intrahepatic portosyste-
mic shunt, and octreotide with total parenteral nutrition.5References
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